Investigational Drug Details
| Drug ID: | D504 |
| Drug Name: | Polyunsaturated Fatty Acids |
| Synonyms: | Opti-EPA; PUFA |
| Type: | Supplement |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | -- |
| CasNo: | -- |
| Repositioning for NAFLD: | No |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Phase 2 completed (NCT00323414: PUFA provided no benefit over placebo in NASH patients with diabetes. The effects of PUFA on histology and insulin resistance were inferior to placebo. These data provide no support for PUFA supplements in NASH.) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0361 | NCT00323414 | Phase 2 | Completed | Has Results | April 2006 | February 23, 2018 | Details |
| L0513 | ChiCTR1800014419 | Other | Recruiting | No Results Available | 12/01/2018 | 15 January 2018 | Details |
| L0520 | IRCT2017103030489N2 | Phase 2/Phase 3 | Not Recruiting | No Results Available | 16/11/2017 | 22 February 2018 | Details |
| L0533 | NCT01056133 | Phase 2 | Not recruiting | No Results Available | 22/01/2010 | 23 May 2016 | Details |
| L0558 | IRCT2016102530489N1 | Phase 2/Phase 3 | Not Recruiting | No Results Available | 06/02/2017 | 22 February 2018 | Details |
| L0676 | ISRCTN81956288 | Not applicable | Not Recruiting | No Results Available | 19/05/2010 | 17 October 2016 | Details |
| L0813 | RBR-8dp876 | Not applicable | Not Recruiting | No Results Available | 19/09/2017 | 7 February 2022 | Details |
| L0823 | NCT03132662 | Not applicable | Not recruiting | No Results Available | 03/04/2017 | 12 December 2020 | Details |
| L0835 | NCT03047668 | Not applicable | Recruiting | No Results Available | 21/11/2016 | 12 December 2020 | Details |
| L0911 | NCT01992809 | Phase 3 | Not recruiting | No Results Available | 07/11/2013 | 19 February 2015 | Details |
| L0984 | NCT00230113 | Phase 2 | Not recruiting | No Results Available | 29/09/2005 | 19 February 2015 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00148 | 35208265 | Metabolites | Plasma Oxylipin Profile Discriminates Ethnicities in Subjects with Non-Alcoholic Steatohepatitis: An Exploratory Analysis. | Details |
| A00296 | 35147302 | Hepatol Commun | Effect of Omega-3 Polyunsaturated Fatty Acids on Lipid Metabolism in Patients With Metabolic Syndrome and NAFLD. | Details |
| A00460 | 35072542 | Antioxid Redox Signal | SPECIALIZED PRO-RESOLVING MEDIATORS DERIVED FROM N-3 POLYUNSATURATED FATTY ACIDS: ROLE IN METABOLIC SYNDROME AND RELATED COMPLICATIONS. | Details |
| A01075 | 34877270 | World J Clin Cases | Pharmaconutrition strategy to resolve SARS-CoV-2-induced inflammatory cytokine storm in non-alcoholic fatty liver disease: Omega-3 long-chain polyunsaturated fatty acids. | Details |
| A01186 | 34836021 | Nutrients | Euphausia pacifica (North Pacific Krill): Review of Chemical Features and Potential Benefits of 8-HEPE against Metabolic Syndrome, Dyslipidemia, NAFLD, and Atherosclerosis. | Details |
| A01206 | 34829779 | Biomedicines | Sex-Dependent Effects of Eicosapentaenoic Acid on Hepatic Steatosis in UCP1 Knockout Mice. | Details |
| A01257 | 34813379 | Metab Syndr Relat Disord | The Myristic Acid:Docosahexaenoic Acid Ratio Versus the n-6 Polyunsaturated Fatty Acid:n-3 Polyunsaturated Fatty Acid Ratio as Nonalcoholic Fatty Liver Disease Biomarkers. | Details |
| A01298 | 34798124 | Biochem Pharmacol | CYP4V2 fatty acid omega hydroxylase, a druggable target for the treatment of metabolic associated fatty liver disease (MAFLD). | Details |
| A01348 | 34779464 | Food Funct | MUFA in metabolic syndrome and associated risk factors: is MUFA the opposite side of the PUFA coin? | Details |
| A01652 | 34667947 | JHEP Rep | New targets for NAFLD. | Details |
| A01785 | 34618982 | FASEB J | Omega-3 carboxylic acids and fenofibrate differentially alter plasma lipid mediators in patients with non-alcoholic fatty liver disease. | Details |
| A01936 | 34558838 | Hepatol Commun | Dietary Risks for Liver Mortality in NAFLD: Global Burden of Disease Data. | Details |
| A01972 | 34547171 | Liver Int | The role of hepatic lipid composition in obesity-related metabolic disease. | Details |
| A02009 | 34532024 | Food Sci Nutr | ω3PUFAs improve hepatic steatosis in postnatal overfed rats and HepG2 cells by inhibiting acetyl-CoA carboxylase. | Details |
| A02106 | 34505434 | Se Pu | [Identification of LAMTOR1-regulated metabolites using ultra-performance liquid chromatography coupled with time-of-flight mass spectrometry in malignant transformation of liver inflammation]. | Details |
| A02668 | 34291454 | Eur J Clin Invest | Omega-3 phospholipids and obesity-associated NAFLD: Potential mechanisms and therapeutic perspectives. | Details |
| A02708 | 34277236 | Cureus | The Significance of the Mediterranean Diet in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review. | Details |
| A02728 | 34270928 | Cell Metab | FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. | Details |
| A02873 | 34210457 | Rev Gastroenterol Mex (Engl Ed) | Dietary and sociodemographic factors associated with nonalcoholic fatty liver in obese pediatric patients. | Details |
| A02942 | 34190160 | Medicine (Baltimore) | A nomogram incorporated lifestyle indicators for predicting nonalcoholic fatty liver disease. | Details |